Oncolytics Biotech Inc. Q1 FY2024 earnings call

• Oncolytics' mission is to bring pelareorep to cancer patients quickly, transitioning to a late-stage cancer company. - Pelareorep is an immunotherapeutic that selectively replicates in tumors, introduces double-stranded RNA, and synergizes with multiple cancer treatments. - Progress in breast and pancreatic cancer trials, including GOBLET study expansions (anal cancer cohort expansion, new pancreatic cancer cohort with modified FOLFIRINOX), Type C meeting with FDA for breast cancer program, and upcoming milestones like reporting BRACELET-1 survival data.

No specific product segment financial performance with absolute terms and revenue contribution % provided in the transcript.

• Intend to provide guidance on breast cancer registration path in H1 2024. - Enroll first patient in Cohort five of GOBLET study in pancreatic cancer in H1 2024. - Expect to report BRACELET-1 overall survival data in H2 2024. - Expansion of anal cancer cohort in GOBLET study could open new registrational indication.

• Factors including results of current or pending clinical trials, risks associated with intellectual property protection, financial projections, actions by regulatory agencies, and other factors detailed in company filings with SEDAR and the SEC.

Q: Could provide more color on the potential design of a pivotal study in metastatic breast cancer with pelareorep?

A: Discussion on meeting with FDA regarding population, endpoints; modeling on relevant studies.

Q: Question on interaction between two pancreatic cancer trials and go forward plan?

A: Explanation of T-cell response in different cohorts and plans for first-line studies.

Q: Data from ASCO on mFOLFIRINOX trial?

A: Clarification that no data from ongoing trial is presented at ASCO